Welcome!

News Feed Item

Acquisitions, Successful Clinical Trials, and Financial Results - Research Report on Medtronic, Osiris, Community Health Systems, Dendreon, and Insys Therapeutics

NEW YORK, August 21, 2013 /PRNewswire/ --

Editor Note: For more information about this release, please scroll to bottom.

Today, Investors' Reports announced new research reports highlighting Medtronic, Inc. (NYSE: MDT), Osiris Therapeutics, Inc. (NASDAQ: OSIR), Community Health Systems (NYSE: CYH), Dendreon Corporation (NASDAQ: DNDN), and Insys Therapeutics Inc. (NASDAQ: INSY). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.

Medtronic, Inc. Research Report

On August 12, 2013, Medtronic Inc. (Medtronic) announced the closing of its acquisition of Cardiocom, a privately held developer and provider of telehealth and patient services for the management of chronic diseases, in an all cash transaction valued at $200 million. Commenting on the acquisition, Omar Ishrak, Chairman and CEO of Medtronic, said, "The acquisition of Cardiocom is one step we are taking toward providing a combination of products and solutions that can help address those challenges. With our first integration of this technology focused on heart failure, we will have the unique opportunity to combine our leading diagnostics, therapies and patient management solutions. This combination will strengthen our ability to partner with providers and payers to help them reduce cost and improve quality." The Company expects that the net income from this transaction will be neutral to its FY 2014 earnings. The Full Research Report on Medtronic, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.investorsreports.com/report/2013-08-14/MDT]

Osiris Therapeutics, Inc. Research Report

On August 13, 2013, Osiris Therapeutics Inc. (Osiris) reported that its multi-center, randomized, controlled clinical trial comparing the safety and efficacy of Grafix to standard of care in patients with chronic diabetic foot ulcers had met pre-specified stopping rules for overwhelming effectiveness as determined by the data monitoring committee during a planned interim analysis. The Company stated that for the study's primary endpoint, 62% patients receiving Grafix had complete wound closure compared to only 21% (p < 0.0001) patients who received conventional treatment for their wounds (a relative improvement of 191%). The Company further stated that the trial reached statistical significance in favor of Grafix on all top-line secondary endpoints, demonstrating faster wound closure and a reduction in the number of treatments needed to achieve wound closure. According to the Company, the study showed that patients randomized to receive standard of care were 74% more likely to experience an adverse effect than those receiving Grafix (p=0.008). The Full Research Report on Osiris Therapeutics, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.investorsreports.com/report/2013-08-14/OSIR]

Community Health Systems Research Report

On August 12, 2013, Community Health Systems, Inc. (Community Health Systems) announced that the Company and Community Health Systems (CHS), its wholly owned subsidiary, have entered into an amendment (the Amendment) of their existing credit agreement dated July 25, 2007, as amended and restated as of November 5, 2010, February 2, 2012, as further amendment August 3, 2012 and as of November 27, 2012 (the Credit Agreement), effective on the date of the announcement. Community Health Systems said that the amendment provides for increased flexibility to incur debt by modifying certain terms of the Credit Agreement, including the maximum leverage ratio and secured leverage ratio covenant levels. Community Health Systems added that the amendment includes pricing protection for certain extended term loans, which specifies an increased margin in certain instances. According to the Company, the amendment also provides for a total leverage-based step up to the applicable margin of the extended term loans and the non-extended term loans, though the pricing of the loans under the Credit Agreement will otherwise remain unchanged. The Full Research Report on Community Health Systems - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.investorsreports.com/report/2013-08-14/CYH]

Dendreon Corporation Research Report

On August 8, 2013, Dendreon Corporation (Dendreon) reported its Q2 2013 financial results. The Company's total revenue declined 8.3% YoY to $73.3 million during the quarter. Net loss was $68.8 million, or $0.45 per diluted share, in Q2 2013, compared to a net loss of $96.1 million, or $0.65 per diluted share, in Q2 2012. Commenting on the results, John H. Johnson, Chairman, President and CEO of Dendreon, said, "During the second quarter, we made progress turning around what was a challenging first quarter, with solid growth in large accounts where we are focused. Urology led the way, with 37% quarter-over-quarter growth, and our highest-ever sales in this segment. We have received supportive feedback from physicians, patients and key opinion leaders about PROVENGE, and remain focused on improving utilization through our direct-to-consumer advertising campaign, which is generating positive early indicators." The Full Research Report on Dendreon Corporation - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.investorsreports.com/report/2013-08-14/DNDN]

Insys Therapeutics Inc. Research Report

On August 13, 2013, Insys Therapeutics Inc. (Insys Therapeutics) reported its Q2 2013 financial results. The Company's net revenue increased 431.8% YoY to $18.8 million during the quarter. Net income was $4.5 million, or $0.26 per diluted share, in Q2 2013, compared to a net loss of $6.4 million, or $0.68 per diluted share, in Q2 2012. Commenting on the results, Michale L. Babich, President and CEO of Insys Therapeutics, said, "Our strong second quarter results were driven by continued uptake of Subsys." He added, "The continued growth we have achieved allows us to accelerate reinvestment in both our research and development and sales and marketing efforts." The Full Research Report on Insys Therapeutics Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.investorsreports.com/report/2013-08-14/INSY]

EDITOR NOTES:

  1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.
  2. Information in this release is fact checked and produced on a best efforts basis and reviewed by a CFA. However, we are only human and are prone to making mistakes. If you notice any errors or omissions, please notify us below.
  3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
  4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco@EquityNewsNetwork.com.
  5. For any urgent concerns or inquiries, please contact us at compliance@EquityNewsNetwork.com.
  6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research@EquityNewsNetwork.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider has, through Chartered Financial Analysts, only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

SOURCE Investors' Reports

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
With the proliferation of both SQL and NoSQL databases, organizations can now target specific fit-for-purpose database tools for their different application needs regarding scalability, ease of use, ACID support, etc. Platform as a Service offerings make this even easier now, enabling developers to roll out their own database infrastructure in minutes with minimal management overhead. However, this same amount of flexibility also comes with the challenges of picking the right tool, on the right ...
“We're a global managed hosting provider. Our core customer set is a U.S.-based customer that is looking to go global,” explained Adam Rogers, Managing Director at ANEXIA, in this SYS-CON.tv interview at 18th Cloud Expo, held June 7-9, 2016, at the Javits Center in New York City, NY.
In today's uber-connected, consumer-centric, cloud-enabled, insights-driven, multi-device, global world, the focus of solutions has shifted from the product that is sold to the person who is buying the product or service. Enterprises have rebranded their business around the consumers of their products. The buyer is the person and the focus is not on the offering. The person is connected through multiple devices, wearables, at home, on the road, and in multiple locations, sometimes simultaneously...
Security, data privacy, reliability and regulatory compliance are critical factors when evaluating whether to move business applications from in-house client hosted environments to a cloud platform. In her session at 18th Cloud Expo, Vandana Viswanathan, Associate Director at Cognizant, In this session, will provide an orientation to the five stages required to implement a cloud hosted solution validation strategy.
"We host and fully manage cloud data services, whether we store, the data, move the data, or run analytics on the data," stated Kamal Shannak, Senior Development Manager, Cloud Data Services, IBM, in this SYS-CON.tv interview at 18th Cloud Expo, held June 7-9, 2016, at the Javits Center in New York City, NY.
China Unicom exhibit at the 19th International Cloud Expo, which took place at the Santa Clara Convention Center in Santa Clara, CA, in November 2016. China United Network Communications Group Co. Ltd ("China Unicom") was officially established in 2009 on the basis of the merger of former China Netcom and former China Unicom. China Unicom mainly operates a full range of telecommunications services including mobile broadband (GSM, WCDMA, LTE FDD, TD-LTE), fixed-line broadband, ICT, data communica...
All organizations that did not originate this moment have a pre-existing culture as well as legacy technology and processes that can be more or less amenable to DevOps implementation. That organizational culture is influenced by the personalities and management styles of Executive Management, the wider culture in which the organization is situated, and the personalities of key team members at all levels of the organization. This culture and entrenched interests usually throw a wrench in the work...
Zerto exhibited at SYS-CON's 18th International Cloud Expo®, which took place at the Javits Center in New York City, NY, in June 2016. Zerto is committed to keeping enterprise and cloud IT running 24/7 by providing innovative, simple, reliable and scalable business continuity software solutions. Through the Zerto Cloud Continuity Platform™, organizations can seamlessly move and protect virtualized workloads between public, private and hybrid clouds. The company’s flagship product, Zerto Virtual...
As businesses adopt functionalities in cloud computing, it’s imperative that IT operations consistently ensure cloud systems work correctly – all of the time, and to their best capabilities. In his session at @BigDataExpo, Bernd Harzog, CEO and founder of OpsDataStore, will present an industry answer to the common question, “Are you running IT operations as efficiently and as cost effectively as you need to?” He will expound on the industry issues he frequently came up against as an analyst, and...
WebRTC is about the data channel as much as about video and audio conferencing. However, basically all commercial WebRTC applications have been built with a focus on audio and video. The handling of “data” has been limited to text chat and file download – all other data sharing seems to end with screensharing. What is holding back a more intensive use of peer-to-peer data? In her session at @ThingsExpo, Dr Silvia Pfeiffer, WebRTC Applications Team Lead at National ICT Australia, looked at differ...
With major technology companies and startups seriously embracing IoT strategies, now is the perfect time to attend @ThingsExpo 2016 in New York. Learn what is going on, contribute to the discussions, and ensure that your enterprise is as "IoT-Ready" as it can be! Internet of @ThingsExpo, taking place June 6-8, 2017, at the Javits Center in New York City, New York, is co-located with 20th Cloud Expo and will feature technical sessions from a rock star conference faculty and the leading industry p...
IoT offers a value of almost $4 trillion to the manufacturing industry through platforms that can improve margins, optimize operations & drive high performance work teams. By using IoT technologies as a foundation, manufacturing customers are integrating worker safety with manufacturing systems, driving deep collaboration and utilizing analytics to exponentially increased per-unit margins. However, as Benoit Lheureux, the VP for Research at Gartner points out, “IoT project implementers often un...
SYS-CON Events announced today that Technologic Systems Inc., an embedded systems solutions company, will exhibit at SYS-CON's @ThingsExpo, which will take place on June 6-8, 2017, at the Javits Center in New York City, NY. Technologic Systems is an embedded systems company with headquarters in Fountain Hills, Arizona. They have been in business for 32 years, helping more than 8,000 OEM customers and building over a hundred COTS products that have never been discontinued. Technologic Systems’ pr...
SYS-CON Events announced today that IoT Now has been named “Media Sponsor” of SYS-CON's 20th International Cloud Expo, which will take place on June 6–8, 2017, at the Javits Center in New York City, NY. IoT Now explores the evolving opportunities and challenges facing CSPs, and it passes on some lessons learned from those who have taken the first steps in next-gen IoT services.
SYS-CON Events announced today that WineSOFT will exhibit at SYS-CON's 20th International Cloud Expo®, which will take place on June 6-8, 2017, at the Javits Center in New York City, NY. Based in Seoul and Irvine, WineSOFT is an innovative software house focusing on internet infrastructure solutions. The venture started as a bootstrap start-up in 2010 by focusing on making the internet faster and more powerful. WineSOFT’s knowledge is based on the expertise of TCP/IP, VPN, SSL, peer-to-peer, mob...